DSP-0390
Phase 1Active 1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High Grade Glioma
Conditions
High Grade Glioma, Glioblastoma Multiforme
Trial Timeline
Sep 8, 2021 → Oct 31, 2026
NCT ID
NCT05023551About DSP-0390
DSP-0390 is a phase 1 stage product being developed by Sumitomo Pharma for High Grade Glioma. The current trial status is active. This product is registered under clinical trial identifier NCT05023551. Target conditions include High Grade Glioma, Glioblastoma Multiforme.
What happened to similar drugs?
3 of 20 similar drugs in High Grade Glioma were approved
Approved (3) Terminated (6) Active (12)
🔄olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06636162 | Phase 1 | Recruiting |
| NCT05023551 | Phase 1 | Active |
Competing Products
20 competing products in High Grade Glioma